Peter De Cruz on the PREDICT-UC trial of intensified versus standard dose infliximab for steroid-refractory acute severe ulcerative colitis

Shahida Din and Beatriz Gros on the harms associated with receiving placebo in trials of drugs for inflammatory bowel disease

Arndt Vogel on the NALIRICC trial of nanoliposomal irinotecan in pretreated advanced biliary tract cancer

Nancy Baxter on the duration of colorectal cancer risk reduction with a complete colonoscopy

Sanna Nybacka and Magnus Simrén on a trial of low FODMAP diets versus low carbohydrate diets in IBS

Nuru Noor on the PROFILE trial of biomarker-stratified treatment in newly diagnosed Crohn's disease

Yusuke Shimakawa on a simple score for hepatitis B treatment eligibility in Africa

Mads Israelsen on validating the new steatotic liver disease nomenclature in people with excessive alcohol intake

Louise Dye on the role of expectancy and gluten in non-coeliac gluten sensitivity

Tzu-Chan Hong on the primary antibiotic resistance of Helicobacter pylori in the Asia-Pacific region

Sarah Moen on metachronous colorectal cancer risk according to Lynch syndrome pathogenic variant after colectomy

Anna Emilie Kann on the causes of mortality in patients with alcohol-related liver disease

Robert Krouse on surgical versus non-surgical management of malignant bowel obstruction

Marc Rothenberg on a trial of benralizumab in eosinophilic gastritis

Michael Pavlides on non-invasive tests for predicting clinical outcomes in non-alcoholic fatty liver disease

Jasmohan Bajaj on global disparities in mortality and liver transplantation in hospitalised patients with cirrhosis

Adelina Artenie on the incidence of HIV and HCV in people who inject drugs

Johan Burisch on the costs of inflammatory bowel disease in high-income settings

Edouard Louis on the SPARE trial of infliximab or immunosuppressant withdrawal in Crohn’s disease

Paula Ghaneh on the ESPAC5 trial of neoadjuvant therapy in borderline resectable pancreatic cancer